Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2- Breast Cancer

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Related Keywords

Portugal ,Lisbon ,Lisboa ,Fatima Cardoso ,Breast Unit At Champalimaud Clinical Center ,Breast Unit ,Champalimaud Clinical Center ,Eastern Europe ,Pembrolizumab ,Neoadjuvant Pembrolizumab ,Keynote 756 ,Jesmo ,Breast Cancer ,